Edition:
India

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

568.70INR
10:13am IST
Change (% chg)

Rs5.65 (+1.00%)
Prev Close
Rs563.05
Open
Rs567.00
Day's High
Rs571.75
Day's Low
Rs562.85
Volume
39,320
Avg. Vol
200,990
52-wk High
Rs704.75
52-wk Low
Rs458.25

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited is a pharmaceutical company. The Company's business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company offers APIs, formulations and veterinary products. As of March 31, 2015, the Company offered its services across five continents across the world. It offers... (more)

Overall

Beta: 0.38
Market Cap(Mil.): Rs455,807.81
Shares Outstanding(Mil.): 803.61
Dividend: 2.00
Yield (%): 0.35

Financials

  CIPL.BO Industry Sector
P/E (TTM): 42.75 36.75 36.56
EPS (TTM): 13.27 -- --
ROI: -- 14.63 14.06
ROE: -- 15.43 14.98

Morning News Call - India, August 16

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08162016.pdf FACTORS TO WATCH 9:30 am: RBI Governor Raghuram Rajan and Deputy Governor S.S. Mundra at FICCI-IBA annual banking conference in Mumbai. 12:00 pm: Government to release July wholesale price inflation data in New Delhi. 4:30 pm: Banks Board Bureau Chairman Vinod Rai delivers a lecture at central vigilance commission event in New Delhi.

16 Aug 2016

Cipla first quarter profit lags estimates; names new CEO

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, reported a lower-than-expected quarterly profit as revenues in its home market were hit by government measures to cut drug prices.

12 Aug 2016

India's Cipla Q1 profit lags estimates; names new CEO

MUMBAI, Aug 12 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a lower-than-expected quarterly profit as revenues in its home market were hit by government measures to cut drug prices.

12 Aug 2016

Cipla Q4 profit lags due to one-off charges in Europe, emerging markets

MUMBAI Cipla Ltd, India's fifth-largest drugmaker by sales, reported a 69 percent fall in its quarterly profit, well below analysts' forecasts, due to one-off costs related to its business in Europe and some emerging markets.

24 May 2016

UPDATE 1-India's Cipla Q4 profit lags due to one-off charges in Europe, emerging markets

* Says exiting some emerging markets, modifying Europe business

24 May 2016

India drugmaker Cipla profit falls short of forecast, down 69 pct

MUMBAI, May 24 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a fall of 69 percent in its quarterly earnings on Tuesday, far short of analysts' forecasts.

24 May 2016

Earnings vs. Estimates